|
|
List of Publications
2006
1. Spanakis E, Sidiropoulos P, Papadakis J, Ganotakis E, Katsikas G, Karvounaris
S, Bizaki A, Kritikos H, Boumpas DT. Modest but sustained increase of
serum high density lipoprotein cholesterol levels in patients with inflammatory
arthritides treated with infliximab. J Rheumatol. 2006 Dec;33(12):2440-6
2. Thabet et al FCRL3 promoter 169CC homozygosity is associated with
susceptibility to rheumatoid arthritis in Dutch Caucasians. Ann Rheum
Dis 2006: Dec 19.
3. Michou L et al Linkage proof for PTPN22, a rheumatoid arthritis susceptibility
gene and a human autoimmunity gene. Proc Natl Acad Sc i 2007 Jan 30; 104(5):1649-54.
4. Wang, J. , A. Ioan-Facsinay, E. I. H. van der Voort, T. W. J. Huizinga
and R. E. M. Toes. Transient expression of FOXP3 in human activated non-regulatory
CD4+ T cells. Eur. J. Immunol. 2007. 37, 129-138.
5. Charbonnier, L. M., L. M. van Duivenvoorde, F. Apparailly, C. Cantos,
W. G. Han, D. Noel, C. Duperray, T. W. Huizinga, R. E. Toes, C. Jorgensen,
and P. Louis-Plence. Immature dendritic cells suppress collagen-induced
arthritis by in vivo expansion of CD49b+ regulatory T cells. J.Immunol.
2006. 177:3806-3813.
6. Linn-Rasker, S. P., van der Helm-van Mil AH, F. A. van Gaalen, M.
Kloppenburg, R. R. de Vries, S. le Cessie, F. C. Breedveld, R. E. Toes,
and T. W. Huizinga.
Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis
patients who carry HLA-DRB1 shared epitope alleles. Ann.Rheum.Dis. 2006.
65:366-371.
7. Linn-Rasker, S. P., van der Helm-van Mil AH, F. C. Breedveld, and
T. W. Huizinga. Arthritis of the large joints - in particular, the knee
- at first presentation is predictive for a high level of radiological
destruction of the small joints in rheumatoid arthritis. Ann.Rheum.Dis.
2007. 66:646-650. ?Ref ID: 32
8. de Vries, R. R., T. W. Huizinga, and R. E. Toes. 2006. HLA and RA revisited:
citrullinated food for the SE hypothesis, the DR6 effect, and NIMA. Hum.Immunol.
67:454-459.
9. van der Helm-van Mil AH, F. C. Breedveld, and T. W. Huizinga.. Aspects
of early arthritis. Definition of disease states in early arthritis: remission
versus minimal disease activity. Arthritis Res.Ther. 2006 8:216.?Ref ID:
49
10. van der Helm-van Mil AH, M. Kern, P. K. Gregersen, and T. W. Huizinga.
Variation in radiologic joint destruction in rheumatoid arthritis differs
between monozygotic and dizygotic twins and pairs of unrelated patients.
Arthritis Rheum. 2006. 54:2028-2030.?Ref ID: 52
11. van der Helm-van Mil AH, K. N. Verpoort, F. C. Breedveld, T. W. Huizinga,
R. E. Toes, and R. R. de Vries. The HLA-DRB1 shared epitope alleles are
primarily a risk factor for anti-cyclic citrullinated peptide antibodies
and are not an independent risk factor for development of rheumatoid arthritis.
Arthritis Rheum. 2006. 54:1117-1121.?Ref ID: 54
12. van Duivenvoorde, L. M., G. J. van Mierlo, Z. F. Boonman, and R. E.
Toes. Dendritic cells: vehicles for tolerance induction and prevention
of autoimmune diseases. Immunobiology 2006. 211:627-632.?Ref ID: 78
13. van Duivenvoorde, L. M., W. G. Han, A. M. Bakker, P. Louis-Plence,
L. M. Charbonnier, F. Apparailly, E. I. van der Voort, C. Jorgensen, T.
W. Huizinga, and R. E. Toes. Immunomodulatory dendritic cells inhibit
Th1 responses and arthritis via different mechanisms. 2007. J.Immunol.
179:1506-1515.?Ref ID: 7
14. Vries-Bouwstra, J., S. le Cessie, C. Allaart, F. Breedveld, and T.
Huizinga.
Using predicted disease outcome to provide differentiated treatment of
early rheumatoid arthritis. J.Rheumatol. 2006. 33:1747-1753.?Ref ID: 50
15. Wesoly, J., J. A. Wessels, H. J. Guchelaar, and T. W. Huizinga. Genetic
markers of treatment response in rheumatoid arthritis. Curr.Rheumatol.Rep.
2006. 8:369-377.?Ref ID: 42
16. Wessels, J. A., J. K. Vries-Bouwstra, B. T. Heijmans, P. E. Slagboom,
Y. P. Goekoop-Ruiterman, C. F. Allaart, P. J. Kerstens, D. van Zeben,
F. C. Breedveld, B. A. Dijkmans, T. W. Huizinga, and H. J. Guchelaar.
Efficacy and toxicity of methotrexate in early rheumatoid arthritis are
associated with single-nucleotide polymorphisms in genes coding for folate
pathway enzymes. Arthritis Rheum. 2006. 54:1087-1095.?Ref ID: 55
17. Klareskog L, Padyukov L, Lorentzen J, Alfredsson L
Mechanisms of Disease: genetic susceptibility and environmental triggers
in the development of rheumatoid arthritis. Nat Cli n Pract Rheumatol
2006;2:425-433
18. L Michou , P Croiseau, E Petit-Teixeira, S Tezenas du Montcel, ?I
Lemaire, C Pierlot, J Osorio , W Frigui, S Lasbleiz, P Quillet, T Bardin,
B Prum, F Clerget-Darpoux, ?F Cornélis and the European Consortium
on Rheumatoid Arthritis Families
Validation of the reshaped shared epitope HLA-DRB1 classification in rheumatoid
arthritis. Arthritis Research & Therapy 2006, 8:R79 (doi:10.1186/ar1949)
19. Mahr S, Burmester GR, Hilke D, Gobel U, Grutzkau A, Haupl T, Hauschild
M, Koczan D, Krenn V, Neidel J, Perka C, Radbruch A, Thiesen HJ, Muller
B.
Cis- and trans-acting gene regulation is associated with osteoarthritis.
Arthritis Research & Therapy 2006, 8:R79
20. Makrygiannakis D, Af Klint E, Catrina SB, Botusan IR, Klareskog E,
Klareskog L, Ulfgren AK, Catrina AI. Intraarticular corticosteroids decrease
synovial RANKL expression in inflammatory arthritis. Arthritis Rheum.
2006 May;54(5):1463-72.
21. Kruithof E, et al; OMERACT Special Interest Group on Synovial Analysis
in Clinical Trials. Identification of synovial biomarkers of response
to experimental treatment in early-phase clinical trials in spondyloarthritis.
Arthritis Rheum. 2006 Jun;54(6):1795- 804.
22. Remans, P. H., C. A. Wijbrandts, M. E. Sanders, R. E. Toes, F. C.
Breedveld, P. P. Tak, J. M. van Laar, and K. A. Reedquist. CTLA-4IG suppresses
reactive oxygen species by preventing synovial adherent cell-induced inactivation
of Rap1, a Ras family GTPASE mediator of oxidative stress in rheumatoid
arthritis T cells. Arthritis Rheum. 2006. 54:3135-3143.?
23. Steenvoorden, M. M., T. C. Tolboom, P. G. van der, C. Lowik, C. P.
Visser, J. Degroot, A. C. Gittenberger-DeGroot, M. C. DeRuiter, B. J.
Wisse, T. W. Huizinga, and R. E. Toes. Transition of healthy to diseased
synovial tissue in rheumatoid arthritis is associated with gain of mesenchymal/fibrotic
characteristics. Arthritis Res.Ther. 2006. 8:R165.
24. Steenvoorden, M. M., van der Helm-van Mil AH, G. Stoeken, R. A. Bank,
R. R. Devries, T. W. Huizinga, J. Degroot, and R. E. Toes. The RAGE G82S
polymorphism is not associated with rheumatoid arthritis independently
of HLA-DRB1*0401. Rheumatology.(Oxford) 2006. 45:488-490.
25. Steenvoorden, M. M., T. W. Huizinga, N. Verzijl, R. A. Bank, H. K.
Ronday, H. A. Luning, F. P. Lafeber, R. E. Toes, and J. Degroot. Activation
of receptor for advanced glycation end products in osteoarthritis leads
to increased stimulation of chondrocytes and synoviocytes. Arthritis Rheum.
2006. 54:253-263.
26. Thabet, M. M. and T. W. Huizinga. Drug evaluation: apratastat, a
novel TACE/MMP inhibitor for rheumatoid arthritis. Curr.Opin.Investig.Drugs
2006. 7:1014-1019.
27. Tolboom, T. C., Y. H. Zhang, N. V. Henriquez, R. G. Nelissen, R.
E. Toes, M. H. Noteborn, and T. W. Huizinga. Fibroblast-like synoviocytes
from patients with rheumatoid arthritis are more sensitive to apoptosis
induced by the viral protein, apoptin, than fibroblast-like synoviocytes
from trauma patients. Clin.Exp.Rheumatol. 2006. 24:142-147.
28. van Aken, J., H. van Dongen, S. le Cessie, C. F. Allaart, F. C. Breedveld,
and T. W. Huizinga. Comparison of long term outcome of patients with rheumatoid
arthritis presenting with undifferentiated arthritis or with rheumatoid
arthritis: an observational cohort study. Ann.Rheum.Dis. 2006. 65:20-25.
29. Vencovsky, J. and T. W. Huizinga. . Rheumatoid arthritis: the goal
rather than the health-care provider is key. Lancet 2006 367:450-452.
30. Wessels, J. A., W. M. Kooloos, R. De Jonge, J. K. Vries-Bouwstra,
C. F. Allaart, A. Linssen, G. Collee, P. De Sonnaville, J. Lindemans,
T. W. Huizinga, and H. J. Guchelaar. Relationship between genetic variants
in the adenosine pathway and outcome of methotrexate treatment in patients
with recent-onset rheumatoid arthritis. Arthritis Rheum. 2006. 54:2830-2839.
31. Verpoort, K. N., Jol-van der Zijde CM, Papendrecht-van der Voort
EA, A. Ioan-Facsinay, J. W. Drijfhout, M. J. van Tol, F. C. Breedveld,
T. W. Huizinga, and R. E. Toes. Isotype distribution of anti-cyclic citrullinated
peptide antibodies in undifferentiated arthritis and rheumatoid arthritis
reflects an ongoing immune response. Arthritis Rheum. 2006. 54:3799-3808.?
32. Cantaert T et al. Citrullinated proteins in rheumatoid arthritis:
crucial...but not sufficient! Arthritis Rheum . 2006 Nov;54(11):3381-9.
33. De Rycke L et al. Pathogenesis of spondyloarthritis: insights from
synovial membrane studies. Curr Rheumatol Rep . 2006 Aug;8(4):275-82.
34. Charbonnier, L. M., L. M. van Duivenvoorde, et al. "Immature
Dendritic Cells Suppress Collagen-Induced Arthritis by In Vivo Expansion
of CD49b+ Regulatory T Cells." J Immunol. 2006. 177 (6): 3806-13.
2007
1. Karvounaris SA, Sidiropoulos PI, Papadakis JA, Spanakis EK, Bertsias
GK,?Kritikos HD, Ganotakis ES, Boumpas DT. Metabolic syndrome is common
among middle-to-older aged Mediterranean patients with rheumatoid arthritis
and correlates with disease activity: a retrospective, cross-sectional,
controlled, study.?Ann Rheum Dis. 2007 Jan;66(1):28-33.
2. V Vazgiourakis, P Sidiropoulos, G Bertsias, E Koutsounaki1, E Fragouli1,
A Raptopoulou, H Kritikos, DT Boumpas and GN Goulielmos. Association of
the nitric oxide synthase (eNOS) gene polymorphism with increased risk
for both lupus glomerulonephritis and rheumatoid arthritis in a single
genetically homogeneous population. Lupus (2007) 16, 867–874
3. Lars C. Huber, Joanna Stanczyk, Astrid Juüngel, and Steffen Gay.
Epigenetics in Inflammatory Rheumatic Diseases. Arthritis Rheum, 2007
Nov;56 (11), 3523–3531
4. Lars C. Huber, Matthias Brock, Hossein Hemmatazad, Olivier T. Giger
et al.
Histone Deacetylase/Acetylase Activity in Total Synovial Tissue Derived
From Rheumatoid Arthritis and Osteoarthritis Patients. Arthrits Rheum,
2007 Apr;56 (4), 1087-1093
5. Fabia Brentano, Olivier Schorr, Caroline Ospelt, Joanna Stanczyk,
Renate E. Gay,
Steffen Gay, and Diego Kyburz. Pre–B Cell Colony-Enhancing Factor/Visfatin,
a New Marker of Inflammation in Rheumatoid Arthritis With Proinflammatory
and Matrix-Degrading Activities. Arthritis Rheum, 2007 Sep56; (9), 2829–2839
6. Teixeira VH, Jacq L, Moore J, Lasbleiz S, Hilliquin P, Resende Oliveira
C,
Cornelis F, Petit-Teixeira E. Association and Expression Study of PRKCH
Gene in a French Caucasian Population with Rheumatoid Arthritis. J Clin
Immunol. 2007 Oct 24
7. Michou L, Teixeira VH, Pierlot C, Lasbleiz S, Bardin T, Dieudé
P, Prum B, Cornélis F, Petit-Teixeira E. Associations between genetic
factors, tobacco smoking and autoantibodies in familial and sporadic rheumatoid
arthritis. Ann Rheum Dis. 2007 Jul 27
8. Mejri K, Kallel-Sellami M, Petit-Teixeira E, Abida O, Mbarek H, Zitouni
M, Ben
Ayed M, Teixeira VH, Mokni M, Fazza B, Turki H, Tron F, Gilbert D, Masmoudi
H,
Cornelis F, Makni S. PTPN22 R620W polymorphism is not associated with
pemphigus. Br J Dermatol. 2007 Nov;157(5):1068-9
9. Jacq L, Teixeira VH, Garnier S, Michou L, Dieudé P, Rocha D,
Pierlot C, Lemaire I, Quillet P, Hilliquin P, Mbarek H, Petit-Teixeira
E, Cornélis F. HSPD1 is not a major susceptibility gene for rheumatoid
arthritis in the French Caucasian population. J Hum Genet. 2007;52(12):1036-9
10. Jacq L, Garnier S, Dieudé P, Michou L, Pierlot C, Migliorini
P, Balsa A, Westhovens R, Barrera P, Alves H, Vaz C, Fernandes M, Pascual-Salcedo
D, Bombardieri S, Dequeker J, Radstake TR, Van Riel P, van de Putte L,
Lopes-Vaz A, Glikmans E, Barbet S, Lasbleiz S, Lemaire I, Quillet P, Hilliquin
P, Teixeira VH, Petit-Teixeira E, Mbarek H, Prum B, Bardin T, Cornélis
F; European Consortium on Rheumatoid Arthritis Families. The ITGAV rs3738919-C
allele is associated with rheumatoid arthritis in the European Caucasian
population: a family-based study. Arthritis Res Ther. 2007;9(4):R63
11. Gourraud PA, Dieudé P, Boyer JF, Nogueira L, Cambon-Thomsen
A, Mazières B,
Cornélis F, Serre G, Cantagrel A, Constantin A. A new classification
of HLA-DRB1 alleles differentiates predisposing and protective alleles
for autoantibody production in rheumatoid arthritis. Arthritis Res Ther.
2007;9(2):R27
12. Dieudé P, Goossens M, Cornélis F, Michou L, Bardin T,
Tchernitchko DO; European Consortium on Rheumatoid Arthritis Families.
The TNFRSF1A R92Q mutation is frequent in rheumatoid arthritis but shows
no evidence for association or linkage with the disease. Ann Rheum Dis.
2007 Aug;66(8):1113-5.
13. Cantaert T, Stone MA, Terborg M, Mogg R, de Vries N, Wilson AG, Tak
PP, Baeten?D. A functional polymorphism of TIR-domain-containing adaptor
protein is not?associated with axial spondyloarthritis. Ann Rheum Dis.
2007 Dec 23
14. Poulsom H, Charles P J. Antibodies to citrullinated vimentin are
a specific and sensitive marker for the diagnosis of rheumatoid arthritis.
Clinic Rev Allerg Immunol, DOI 10.1007/s12016-007-8016-3
15. Young-Min S, Cawston T, Marshall N, Coady D, Christgau S, Saxne T,
Robins S,?Griffiths I. Biomarkers predict radiographic progression in
early rheumatoid arthritis and?perform well compared with traditional
markers. Arthritis Rheum. 2007 Oct;56(10):3236-47
16. Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated
with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and
anti-infliximab antibodies.?Rheumatology (Oxford). 2007 Dec;46(12):1828-34
17. Hesselstrand R, Kassner A, Heinegard D, Saxne T. COMP a candidate
molecule in the pathogenesis of systemic sclerosis with a potential as
a disease marker.?Ann Rheum Dis. 2007 Dec 7
18. Mathsson L, Mullazehi M, Wick MC, Sjöberg O, van Vollenhoven
R, Klareskog L, Rönnelid J. Antibodies against citrullinated vimentin
in rheumatoid arthritis: Higher sensitivity and extended prognostic value
concerning future radiographic progression as compared with antibodies
against cyclic citrullinated peptides. Arthritis Rheum. 2007 Dec 28;58(1):36-45
19. Cohen IR, Klareskog L. Antiinflammatory therapy for rheumatoid arthritis?
Arthritis Rheum. 2007 Dec 28;58(1):2-4
20. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis
factor antagonist mechanisms of action: A comprehensive review. Pharmacol
Ther. 2007 Oct 26
21. Kurreeman, F. A., L. Padyukov, R. B. Marques, S. J. Schrodi, M. Seddighzadeh,
G. Stoeken-Rijsbergen, van der Helm-van Mil AH, C. F. Allaart, W. Verduyn,
J. Houwing-Duistermaat, L. Alfredsson, A. B. Begovich, L. Klareskog, T.
W. Huizinga, and R. E. Toes. A Candidate Gene Approach Identifies the
TRAF1/C5 Region as a Risk Factor for Rheumatoid Arthritis. PLoS.Med. 2007.
4:e278
22. Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW, de Bakker
PI, Le JM, Lee HS, Batliwalla F, Li W, Masters SL, Booty MG, Carulli JP,
Padyukov L, Alfredsson L, Klareskog L, Chen WV, Amos CI, Criswell LA,
Seldin MF, Kastner DL, Gregersen PK. STAT4 and the risk of rheumatoid
arthritis and systemic lupus erythematosus. N Engl J Med. 2007 Sep 6;357(10):977-86.
23. Plenge RM, Seielstad M, Padyukov L, Lee AT, Remmers EF, Ding B, Liew
A, Khalili H, Chandrasekaran A, Davies LR, Li W, Tan AK, Bonnard C, Ong
RT, Thalamuthu A, Pettersson S, Liu C, Tian C, Chen WV, Carulli JP, Beckman
EM, Altshuler D, Alfredsson L, Criswell LA, Amos CI, Seldin MF, Kastner
DL, Klareskog L, Gregersen PK. TRAF1-C5 as a Risk Locus for Rheumatoid
Arthritis -- A Genomewide Study. N Engl J Med. 2007 Sep 5;
24. Kallberg H, Padyukov L, Plenge RM, Ronnelid J, Gregersen PK, van der
Helm-van Mil AH, Toes RE, Huizinga TW, Klareskog L, Alfredsson L; Epidemiological
Investigation of Rheumatoid Arthritis study group. Gene-gene and gene-environment
interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of
rheumatoid arthritis. Am J Hum Genet. 2007 May;80(5):867-75. Epub 2007
Apr 2.
25. Olofsson P, Nerstedt A, Hultqvist M, Nilsson EC, Andersson S, Bergelin
A, Holmdahl R. Arthritis suppression by NADPH activation operates through
an interferon-beta pathway. BMC Biol. 2007 May 9; 5:19.
26. Huber LC, Jüngel A, Distler JHW, Moritz F, Gay RE, Michel BA,
Pisetsky DS, Gay S, Distler O. The role of membrane lipids in the induction
of macrophage apoptosis by microparticles. Apoptosis 12:363-374, 2007
27. Kooloos, W. M., D. J. de Jong, T. W. Huizinga, and H. J. Guchelaar.
Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid
arthritis and Crohn's disease. Drug Discov.Today 2007. 12:125-131. ?Ref
ID: 24
28. Hoberg M, Rudert M, Pap T, Klein G, Gay S, Aicher WK. Attachment to
laminin-111 facilitates transforming growth factor beta-induced expression
of matrix metalloproteinase-3 in synovial fibroblasts. Ann Rheum Dis 66:446-51,
2007
29. Huber LC, Brock M, Hemmatazad H, Giger O, Moritz F, Trenkmann M, Distler
JHW, Gay RE, Kolling C, Moch H, Michel BA, Gay S, Distler O, Jungel A.
Histone deacetylase/acetylase activity in total synovial tissue derived
from rheumatoid arthritis and osteoarthritis patients. Arthr Rheum 56:1087-93,
2007
30. Meinecke I, Cinski A, Baier A, Peters MA, Dankbar B, Willie A, Drynda
A, Mendoza H, Gay RE, Hay RT, Ink B, Gay S, Pap T. Modification of nuclear
PML protein by SUMO-1 regulates Fas-induced apoptosis in rheumatoid arthritis
synovial fibroblasts. Proc Natl Acad Sci USA 104:5073-8, 2007
31. Jacq L, Garnier S, Dieude P, Michou L, Pierlot C, Migliorini P, Balsa
A, Westhovens R, Barrera P, Alves H, Vaz C, Fernandes M, Pascual-Salcedo
D, Bombardieri S, Dequeker J, Radstake TR, Van Riel P, van de Putte L,
Lopes-Vaz A, Glikmans E, Barbet S, Lasbleiz S, Lemaire I, Quillet P, Hilliquin
P, Teixeira VH, Petit-Teixeira E, Mbarek H, Prum B, Bardin T, Cornelis
F; the European Consortium on Rheumatoid Arthritis Families. The ITGAV
rs3738919-C allele is associated with rheumatoid arthritis in the European
Caucasian population: a family-based study. Arthritis Res Ther. 2007 Jul
3;9(4):R63
32. Hansson MG. For the safety and benefit of current and future patients.
Pathobiology. 2007;74(4):198-205.
33. Van der Helm –van Mil et al. A rule to predict disease outcome
in patients with recent-onset undifferentiated arthritis to guide individual
treatment decisions, Arthritis Rheum. 2007 Feb;56(2):433-40
34. van der Pouw Kraan TC et al. Rheumatoid arthritis subtypes identified
by genomic profiling of peripheral blood cells: Assignment of a type I
interferon signature in a subpopulation of patients. Ann Rheum Dis . 2007
Jan 12
35. Canete JD et al. Ectopic lymphoid neogenesis in psoriatic arthritis.
Ann Rheum Dis. 2007 Jan 12
36. Bongartz et al. Citrullination in extra-articular manifestations of
rheumatoid arthritis. Rheumatology ( Oxford ). 2007 Jan;46(1):70-5.
37. Bessis, N., D. Lemeiter, L. Laroche, C. Fournier, T. Huizinga, H.
Brok, H. B. 't, and M. C. Boissier. Engraftment of cutaneous fibroblasts
within synovial membrane in a nonhuman primate: short-term results. Joint
Bone Spine 2007. 74:48-51.
40. Wijbrandts CA, Dijkgraaf MG, Kraan MC, Vinkenoog M, Smeets TJ, Dinant
H, Vos?K, Lems WF, Wolbink GJ, Sijpkens DE, Dijkmans BA, Tak P. The clinical
response to infliximab in rheumatoid arthritis is in part dependent on
pre-treatment TNF{alpha} expression in the synovium. Ann Rheum Dis. 2007
Nov 29
41. Grundtman C, Salomonsson S, Dorph C, Bruton J, Andersson U, Lundberg
IE.
Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei
of skeletal muscle in patients with idiopathic inflammatory myopathies.
Arthritis Rheum. 2007 56:674-87.
42. Van der Straaten R, et al. Exploratory analysis of four polymorphisms
in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid
arthritis patients. Pharmacogenomics. 2007 Feb;8(2):141-150.
43. Zhangh Z, et al. TCR{zeta}dim lymphocytes define populations of circulating
effector cells that migrate to inflamed tissues. Blood. 2007 Jan 25;
44. Feitsma AL et. al Risk of progression from undifferentiated arthritis
to rheumatoid arthritis: the effect of the PTPN22 1858T-allele in anti-citrullinated
peptide antibody positive patients. Rheumatology ( Oxford ). 2007 Mar
6
46. Feitsma, A. L., R. E. Toes, A. B. Begovich, A. P. Chokkalingam, R.
R. de Vries, T. W. Huizinga, and van der Helm-van Mil AH. Risk of progression
from undifferentiated arthritis to rheumatoid arthritis: the effect of
the PTPN22 1858T-allele in anti-citrullinated peptide antibody positive
patients. Rheumatology. (Oxford) 2007. 46:1092-1095.
47. Thurlings RM, Wijbrandts CA, Mebius RE, Cantaert T, Dinant H, van
der ?Pouw-Kraan TCTM, Baeten D, Tak PP. Synovial Lymphoid Neogenesis Does
?not Define A Specific Clinical Rheumatoid Arthritis Phenotype. ?Arthritis
Rheumatism 2008 Jun;58(6):1582-9
48. van der Pouw Kraan TC, van Baarsen LG, Wijbrandts CA, Voskuyl AE,
Rustenburg F,Baggen JM, Dijkmans BA, Tak PP, Verweij CL. Expression of
a pathogen-response program in peripheral blood cells defines a subgroup
of Rheumatoid Arthritis patients. Genes Immun. 2007 Oct 11 [Epub ahead
of print].
48. Thurlings RM, Vos K, Wijbrandts CA, Zwinderman A, Gerlag DM, Tak
PP. Synovial tissue response to rituximab: mechanism of action and identification
of biomarkers of response. Ann Rheum Dis. 2007 Oct 26.
49. Vergunst CE, Gerlag DM, Dinant H, Schulz L, Vinkenoog M, Smeets TJ,
Sanders?ME, Reedquist KA, Tak PP. Blocking the receptor for C5a in patients
with rheumatoid arthritis does not reduce synovial inflammation. Rheumatology
(Oxford). 2007 Dec;46(12):1773-8. Epub 2007 Oct 27.
50. Wijbrandts CA, Vergunst CE, Haringman JJ, Gerlag DM, Smeets TJ, Tak
PP. Absence of changes in the number of synovial sublining macrophages
after ineffective treatment for rheumatoid arthritis: Implications for
use of synovial sublining macrophages as a biomarker. Arthritis Rheum.
2007;56:3869-71.
51. van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Rustenburg F,
Baggen JM,Verweij CL, Tak P. Responsiveness to anti-TNF{alpha} therapy
is related to pre-treatment tissue inflammation levels in Rheumatoid Arthritis
patients. Ann Rheum Dis. 2007
52. Adriaansen J, Khoury M, de Cortie CJ, Fallaux FJ, Bigey P, Scherman
D, Gould?DJ, Chernajovsky Y, Apparailly F, Jorgensen C, Vervoordeldonk
MJ, Tak PP. Reduction of arthritis following intra-articular administration
of an adeno-associated virus serotype 5 expressing a disease-inducible
TNF-blocking agent. Ann Rheum Dis. 2007 Sep;66(9):1143-50. Epub 2007 Mar
15.
53. Feitsma AL, Worthington J, van der Helm-van Mil AH, Plant D, Thomson
W, Ursum ?J, van Schaardenburg D, van der Horst-Bruinsma IE, van Rood
JJ, Huizinga TW, Toes?RE, de Vries RR.?Protective effect of noninherited
maternal HLA-DR antigens on rheumatoid?arthritis development.?Proc Natl
Acad Sci U S A. 2007 Dec 11;104(50):19966-70. Epub 2007 Dec 6.
54. Pincus, T., T. W. Huizinga, and Y. Yazici. N-of-1 trial of low-dose
methotrexate and/or prednisolone in lieu of anti-CCP, MRI, or ultrasound,
as first option in suspected rheumatoid arthritis? J.Rheumatol. 2007.
34:250-252.
55. Sigurdsson, S., L. Padyukov, F. A. Kurreeman, U. Liljedahl, A. C.
Wiman, L. Alfredsson, R. Toes, J. Ronnelid, L. Klareskog, T. W. Huizinga,
G. Alm, A. C. Syvanen, and L. Ronnblom. Association of a haplotype in
the promoter region of the interferon regulatory factor 5 gene with rheumatoid
arthritis. Arthritis Rheum. 2007. 56:2202-2210.?
56. Steenvoorden, M. M., R. A. Bank, H. K. Ronday, R. E. Toes, T. W.
Huizinga, and J. Degroot. Fibroblast-like synoviocyte-chondrocyte interaction
in cartilage degradation. Clin.Exp.Rheumatol. 2007. 25:239-245.
57. Steenvoorden MM, Toes RE, Ronday HK, Huizinga TW, Degroot J.?RAGE
activation induces invasiveness of RA fibroblast-like synoviocytes in
vitro.?Clin Exp Rheumatol. 2007 Sep-Oct;25(5):740-2.
58. Swen, J. J., T. W. Huizinga, H. Gelderblom, E. G. de Vries, W. J.
Assendelft, J. Kirchheiner, and H. J. Guchelaar. Translating pharmacogenomics:
challenges on the road to the clinic. PLoS.Med. 2007. 4:e209.
59. Tchetverikov, I., M. C. Kraan, B. van El, R. Hanemaaijer, J. Degroot,
and T. W. Huizinga. Leflunomide and methotrexate reduce levels of activated
mmps in complexes with {alpha}2macroglobulin in serum of rheumatoid arthritis
patients. Ann Rheum Dis. 2008 Jan;67(1):128-30. Epub 2007 Sep 17.
60. Teng YK, Levarht EW, Hashemi M, Bajema IM, Toes RE, Huizinga TW, van
Laar JM.?Immunohistochemical analysis as a means to predict responsiveness
to rituximab?treatment.?Arthritis Rheum. 2007 Dec;56(12):3909-18.
61. Thabet, M. M., J. Wesoly, P. E. Slagboom, R. E. Toes, and T. W. Huizinga.
FCRL3 promoter 169 CC homozygosity is associated with susceptibility to
rheumatoid arthritis in Dutch Caucasians. Ann.Rheum.Dis. 2007. 66:803-806.?
62. Timmer, T. C., B. Baltus, M. Vondenhoff, T. W. Huizinga, P. P. Tak,
C. L. Verweij, R. E. Mebius, and van der Pouw Kraan TC. Inflammation and
ectopic lymphoid structures in rheumatoid arthritis synovial tissues dissected
by genomics technology: identification of the interleukin-7 signaling
pathway in tissues with lymphoid neogenesis. Arthritis Rheum. 2007. 56:2492-2502.
63. van der Helm-van Mil AH, T. W. Huizinga, R. R. de Vries, and R. E.
Toes. Emerging patterns of risk factor make-up enable subclassification
of rheumatoid arthritis. Arthritis Rheum. 2007. 56:1728-1735.?
64. van der Helm-van Mil AH, S. le Cessie, H. van Dongen, F. C. Breedveld,
R. E. Toes, and T. W. Huizinga. A prediction rule for disease outcome
in patients with recent-onset undifferentiated arthritis: how to guide
individual treatment decisions. Arthritis Rheum. 2007. 56:433-440.?
65. van der Helm-van Mil AH, K. N. Verpoort, S. le Cessie, T. W. Huizinga,
R. R. de Vries, and R. E. Toes. The HLA-DRB1 shared epitope alleles differ
in the interaction with smoking and predisposition to antibodies to cyclic
citrullinated peptide. Arthritis Rheum. 2007. 56:425-432.
66. van der Helm-van Mil AH, van der Kooij SM, Allaart CF, Toes RE, Huizinga
TW.?A high body mass index is protective on the amount of joint destruction
in small ?joints in early rheumatoid arthritis.?Ann Rheum Dis. 2007 Oct
26
67. van der, S. R., J. A. Wessels, J. K. Vries-Bouwstra, Y. P. Goekoop-Ruiterman,
C. F. Allaart, J. Bogaartz, M. Tiller, T. W. Huizinga, and H. J. Guchelaar.
Exploratory analysis of four polymorphisms in human GGH and FPGS genes
and their effect in methotrexate-treated rheumatoid arthritis patients.
Pharmacogenomics. 2007. 8:141-150.
68. van Dongen, H., J. van Aken, L. R. Lard, K. Visser, H. K. Ronday,
H. M. Hulsmans, I. Speyer, M. L. Westedt, A. J. Peeters, C. F. Allaart,
R. E. Toes, F. C. Breedveld, and T. W. Huizinga. Efficacy of methotrexate
treatment in patients with probable rheumatoid arthritis: a double-blind,
randomized, placebo-controlled trial. Arthritis Rheum. 2007. 56:1424-1432.?
69. van der Woude D, Huizinga TW.?The battle between anti-cyclic citrullinated
peptide and rheumatoid factor?tests--a winner at last? Nat Clin Pract
Rheumatol. 2007 Dec;3(12):696-7.
70. Verpoort, K. N., Papendrecht-van der Voort EA, van der Helm-van Mil
AH, Jol-van der Zijde CM, M. J. van Tol, J. W. Drijfhout, F. C. Breedveld,
R. R. de Vries, T. W. Huizinga, and R. E. Toes. Association of smoking
with the constitution of the anti-cyclic citrullinated peptide response
in the absence of HLA-DRB1 shared epitope alleles. Arthritis Rheum. 2007.
56:2913-2918.
71. Verpoort KN, Cheung K, Ioan-Facsinay A, van der Helm-van Mil AH,
de?Vries-Bouwstra JK, Allaart CF, Drijfhout JW, de Vries RR, Breedveld
FC, Huizinga ?TW, Pruijn GJ, Toes RE.?Fine specificity of the anti-citrullinated
protein antibody response is?influenced by the shared epitope alleles.?Arthritis
Rheum. 2007 Dec;56(12):3949-52.
72. Vries-Bouwstra, J. K., Y. P. Goekoop-Ruiterman, J. Wesoly, H. J. Hulsmans,
A. J. de Craen, F. C. Breedveld, B. A. Dijkmans, C. F. Allaart, and T.
W. Huizinga. Ex vivo interleukin 1 receptor antagonist production on lipopolysaccharide
stimulation is associated with rheumatoid arthritis and with joint damage.
Ann.Rheum.Dis. 2007. 66:1033-1037.?
73. Wesoly, J., X. Hu, M. M. Thabet, M. Chang, H. Uh, C. F. Allaart, R.
E. Toes, J. J. Houwing-Duistermaat, A. B. Begovich, and T. W. Huizinga.
The 620W allele is the PTPN22 genetic variant conferring susceptibility
to RA in a Dutch population. Rheumatology.(Oxford) 2007. 46:617-621.
74. Wessels, J. A., S. M. van der Kooij, S. le Cessie, W. Kievit, P. Barerra,
C. F. Allaart, T. W. Huizinga, and H. J. Guchelaar. A clinical pharmacogenetic
model to predict the efficacy of methotrexate monotherapy in recent-onset
rheumatoid arthritis. Arthritis Rheum. 2007. 56:1765-1775.
2008
1. van Lent PL, Grevers LC, Blom AB, Arntz OJ, van de Loo FA, van der
Kraan P,Abdollahi-Roodsaz S, Srikrishna G, Freeze H, Sloetjes A, Nacken
W, Vogl T, Roth J, van den Berg WB. Stimulation of chondrocyte-mediated
cartilage destruction by S100A8 in experimental murine arthritis.Arthritis
Rheum. 2008 Dec;58(12):3776-87.
2. van Lent PL, Grevers L, Blom AB, Sloetjes A, Mort JS, Vogl T, Nacken
W, van den Berg WB, Roth J. Myeloid-related proteins S100A8/S100A9 regulate
joint inflammation and cartilage destruction during antigen-induced arthritis.
Ann Rheum Dis. 2008 Dec;67(12):1750-8
3. Sidiropoulos PI, Karvounaris SA, Boumpas DT. Metabolic syndrome in
rheumatic diseases: epidemiology, pathophysiology, and clinical implications.
Arthritis Res Ther. 2008;10(3):207.
4. Ospelt C, Brentano F, Rengel Y, Stanczyk J, Kolling C, Tak PP, Gay
RE, Gay S, Kyburz D; Overexpression of toll-like receptors 3 and 4 in
synovial tissue from patients with early rheumatoid arthritis: toll-like
receptor expression in early and longstanding arthritis. Arthritis Rheum.
2008 Dec;58(12):3684-92.
5. Rihl M, Kellner H, Kellner W, Barthel C, Yu DT, Tak PP, Zeidler H,
Baeten D; Identification of interleukin-7 as a candidate disease mediator
in spondylarthritis. Arthritis Rheum. 2008 Nov;58(11):3430-5.
6. Wijbrandts CA, Remans PH, Klarenbeek PL, Wouters D, van den Bergh
Weerman MA, Smeets TJ, Vervoordeldonk MJ, Baeten D, Tak PP; Analysis of
apoptosis in peripheral blood and synovial tissue very early after initiation
of infliximab treatment in rheumatoid arthritis patients. Arthritis Rheum.
2008 Nov;58(11):3330-9.
7. Vandooren B, Cantaert T, ter Borg M, Noordenbos T, Kuhlman R, Gerlag
D, Bongartz T, Reedquist K, Tak PP, Baeten D; Tumor necrosis factor alpha
drives cadherin 11 expression in rheumatoid inflammation. Arthritis Rheum.
2008 Oct;58(10):3051-62.
8. Oct;58(10):3051-62.?6. Vergunst CE, Gerlag DM, Lopatinskaya L, Klareskog
L, Smith MD, van den Bosch F, Dinant HJ, Lee Y, Wyant T, Jacobson EW,
Baeten D, Tak PP; Modulation of CCR2 in rheumatoid arthritis: a double-blind,
randomized, placebo-controlled clinical trial. Arthritis Rheum. 2008 Jul;58(7):1931-9
9. Cantaert T, Kolln J, Timmer T, van der Pouw Kraan TC, Vandooren B,
Thurlings RM, Cañete JD, Catrina AI, Out T, Verweij CL, Zhang Y,
Tak PP, Baeten D; B lymphocyte autoimmunity in rheumatoid synovitis is
independent of ectopic lymphoid neogenesis. J Immunol. 2008 Jul 1;181(1):785-94.
10. Jun;58(6):1582-9. ?9. Straub RH, Pongratz G, Cutolo M, Wijbrandts
CA, Baeten D, Fleck M, Atzeni F, Grunke M, Kalden JR, Schölmerich
J, Lorenz HM, Tak PP, Sarzi-Puttini P; Increased cortisol relative to
adrenocorticotropic hormone predicts improvement during anti-tumor necrosis
factor therapy in rheumatoid arthritis. Arthritis Rheum. 2008 Apr;58(4):976-84.
11. Baeten D, Kruithof E, Breban M, Tak PP; Spondylarthritis in the absence
of B lymphocytes. Arthritis Rheum. 2008 Mar;58(3):730-3
12. Vandooren B, Cantaert T, Noordenbos T, Tak PP, Baeten D; The abundant
synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral
spondylarthritis is partially disconnected from inflammation. Arthritis
Rheum. 2008 Mar;58(3):718-29.
13. Wijbrandts CA, Dijkgraaf MG, Kraan MC, Vinkenoog M, Smeets TJ, Dinant
H, Vos K, Lems WF, Wolbink GJ, Sijpkens D, Dijkmans BA, Tak PP; The clinical
response to infliximab in rheumatoid arthritis is in part dependent on
pretreatment tumour necrosis factor alpha expression in the synovium.
Ann Rheum Dis. 2008 Aug;67(8):1139-44.
14. Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak
PP; Synovial tissue response to rituximab: mechanism of action and identification
of biomarkers of response. Ann Rheum Dis. 2008 Jul;67(7):917-25.
15. van der Pouw Kraan TC, van Baarsen LG, Wijbrandts CA, Voskuyl AE,
Rustenburg F, Baggen JM, Dijkmans BA, Tak PP, Verweij CL; Expression of
a pathogen-response program in peripheral blood cells defines a subgroup
of rheumatoid arthritis patients. Genes Immun. 2008 Jan;9(1):16-22.
16. Cantaert T, Stone MA, ter Borg M, Mogg R, De Vries N, Wilson AG, Tak
PP, Baeten D; A functional polymorphism of TIR-domain-containing adaptor
protein is not associated with axial spondyloarthritis. Ann Rheum Dis.
2008 May;67(5):720-2.
17. T. Cantaert et al, Exposure to nuclear antigens contributes to the
induction of humoral autoimmunity during TNF blockade, Ann Rheum Dis,
Jul 2008
18. Vandooren B, Cantaert T, van Lierop MJ, Bos E, De Rycke L, Veys EM,
De Keyser F, Bresnihan B, Luyten FP, Verdonk PC, Tak PP, Boots AH, Baeten
D; Melanoma Inhibitory Activity, a biomarker related to chondrocyte anabolism,
is reversibly suppressed by proinflammatory cytokines in rheumatoid arthritis.
Ann Rheum Dis. 2008 Jul 16.
19. Polzer K, Baeten D, Soleiman A, Distler J, Gerlag DM, Tak PP, Schett
G, Zwerina J. TNF blockade increases lymphangiogenesis in murine and human
arthritic joints. Ann Rheum Dis. 2008 Jan 3
20. Cantaert T et al, A functional polymorphism of TIR-domain-containing
adaptor protein is not associated with axial spondyloarthritis. Ann Rheum
Dis. 2008 May;67(5):720-2.
21. M I. Zervoua, Ds Mamoulakisb, C Panierakisb, D T. Boumpas, G N. Goulielmos.
STAT4: A risk factor for type 1 diabetes? Hum Immunol. 2008 Oct;69(10):647-50.
Epub 2008 Aug 12.
22. M I. Zervoua, P Sidiropoulosb, E Petrakic, V Vazgiourakisc, E Krasoudakic,
A Raptopouloub, H Kritikosb, E Choustoulakib, D T. Boumpas, G N. Goulielmosc.
Association of a TRAF1 and a STAT4 gene polymorphism with increased risk
for rheumatoid arthritis in a genetically homogeneous population. Human
Immunology (2008) 69, 567–571
23. E Ammirati, A-C Vermi, D Cianflone, M Banfi, C Foglieni, C Godino,
F Airoldi, L A. Ferri, C L. Gorman, A A. Manfredi, A Maseri, A P. Cope,
C Monaco. Expansion of T-Cell Receptor dim effector T Cells in Acute Coronary
Syndromes Ammirati, Expansion of TCR dimT Cells in ACS. Arterioscler Thromb
Vasc Biol. 2008 Dec;28(12):2305-11.
24. Sheppard J, Kumar K, Buckley CD, Shaw KL, Raza K. 'I just thought
it was normal aches and pains': a qualitative study of decision-making
processes in patients with early rheumatoid arthritis. Rheumatology (Oxford).
2008 Aug 18.
25. Raza K, Mullazehi M, Salmon M, Buckley CD, Rönnelid J. Anti-collagen
type II antibodies in patients with very early synovitis. Ann Rheum Dis.
2008 Sep;67(9):1354-5
26. Kinloch A, Lundberg K, Wait R, Wegner N, Lim NH, Zendman AJ, Saxne
T, Malmström ?V, Venables PJ. Synovial fluid is a site of citrullination
of autoantigens in inflammatory?arthritis. Arthritis Rheum. 2008 Aug;58(8):2287-95
27. Hesselstrand R, Kassner A, Heinegård D, Saxne T. COMP: a candidate
molecule in the pathogenesis of systemic sclerosis with a potential as
a disease marker. Ann Rheum Dis. 2008 Sep;67(9):1242-8.
28. Khoury M, Escriou V, Courties G, Galy A, Yao R, Largeau C, Scherman
D, Jorgensen C, Apparailly F. Efficient suppression of murine arthritis
by combined anticytokine small interfering RNA lipoplexes. Arthritis Rheum.
2008 Aug;58(8):2356-67
29. Haworth O, Hardie DL, Burman A, Rainger GE, Eksteen B, Adams DH, Salmon
M, Nash GB, Buckley CD. A role for the integrin {alpha}6{beta}1 in the
differential distribution of CD4 and CD8 T-cell subsets within the rheumatoid
synovium. Rheumatology (Oxford). 2008 Jul 17
30. van Der Helm-van Mil AH, Detert J, Cessie SL, Filer A, Bastian H,
Burmester GR, Huizinga TW, Raza K. Validation of a prediction rule for
disease outcome in patients with recent-onset undifferentiated arthritis:
Moving toward individualized treatment decision-making. Arthritis Rheum.
2008 Aug;58(8):2241-7.
31. Johnsson L, Hansson MG, Eriksson S, Helgesson G. Patients' refusal
to consent to storage and use of samples in Swedish biobanks: cross sectional
study. BMJ. 2008 Jul 10;337:a345.
32. Hardy RS, Rabbitt EH, Filer A, Emery P, Hewison M, Stewart PM, Gittoes
N, Buckley CD, Raza K, Cooper MS. Local and systemic glucocorticoid metabolism
in inflammatory arthritis. Ann Rheum Dis. 2008 Apr 17
32. Parsonage G, Filer A, Bik M, Hardie D, Lax S, Howlett K, Church LD,
Raza K, Wong SH, Trebilcock E, Scheel-Toellner D, Salmon M, Lord JM, Buckley
CD. Prolonged, granulocyte-macrophage colony-stimulating factor-dependent,
neutrophil survival following rheumatoid synovial fibroblast activation
by IL-17 and TNF alpha. Arthritis Res Ther. 2008;10(2):R47
37. Joanna Stanczyk, Deena M. Leslie Pedrioli, Fabia Brentano, Olga Sanchez-Pernaute
et al. Altered Expression of MicroRNA in Synovial Fibroblasts and Synovial
Tissue in Rheumatoid Arthritis. Arthritis Rheum, 2008 Apr; 58 (4), 1001-1009
38. Maalej A, Petit-Teixeira E, Chabchoub G, Hamad MB, Rebai A, Farid
NR, Cornelis?F, Ayadi H. Lack of Association of VDR Gene Polymorphisms
with Thyroid Autoimmune Disorders: Familial and Case/Control Studies.
J Clin Immunol. 2008 Jan;28(1):21-5
39. Jacq L, Teixeira VH, Garnier S, Petit-Teixeira E, Cornélis
F. The MMP2 rs243865-T allele is not a major genetic factor for rheumatoid
arthritis in the French Caucasian population.?Int J Immunogenet. 2008
Jan 19;
40. Polzer K, Baeten D, Soleiman A, Distler J, Gerlag DM, Tak PP, Schett
G, Zwerina J. TNF blockade increases lymphangiogenesis in murine and human
arthritic joints. Ann Rheum Dis. 2008 Jan 3
41. Baeten D, Kruithof E, Breban M, Tak PP. Spondyloarthritis in the
absence of B lymphocytes. Arthritis Rheum. 2008 Mar;58(3):730-3.
42. Paul P. Tak, Novel approaches for the treatment of rheumatoid arthritis
– Lessons from evaluation of synovial biomarkers in clinical trials.
Best Pract Res Clin Rheumatol 2008 Apr;22(2):311-23.
43. Wessels JA, Huizinga TW, Guchelaar HJ.?Recent insights in the pharmacological
actions of methotrexate in the treatment?of rheumatoid arthritis.?Rheumatology
(Oxford). 2008 Mar;47(3):249-55.
2009
1. Raychaudhuri S, Thomson BP, Remmers EF, Eyre S et al . Genetic variants
at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk.
Nat Genet. 2009 Dec;41(12):1313-8.
2. Mahdi H, Fisher BA, Källberg H, Plant D et al. Specific interaction
between genotype, smoking and autoimmunity to citrullinated alpha-enolase
in the etiology of rheumatoid arthritis. Nat Genet. 2009 Dec;41(12):1319-24.
3. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet. 2009
Feb 21;373(9664):659-72. Epub 2009 Jan 20.
4. Bertsias GK, Nakou M, Choulaki C, Raptopoulou A, Papadimitraki E, Goulielmos
G, Kritikos H, Sidiropoulos P, Tzardi M, Kardassis D, Mamalaki C, Boumpas
DT. Genetic, immunologic, and immunohistochemical analysis of the programmed
death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus.
Arthritis Rheum. 2009 Jan;60(1):207-18
5. Grevers LC, van Lent PL, Koenders MI, Walgreen B, Sloetjes AW, Nimmerjahn
F, Sjef Verbeek J, van den Berg WB. Different amplifying mechanisms of
interleukin-17 and interferon-gamma in Fcgamma receptor-mediated cartilage
destruction in murine immune complex-mediated arthritis.Arthritis Rheum.
2009 Jan 29;60(2):396-407.
6. Cantaert T., de Rycke L., Mavragani C. P., Wijbrandts C. A., Niewold
T. B., Niers T., Vandooren B., Veys E. M., Richel D., Tak P. P., Crow
M. K., Baeten D.: Exposure to nuclear antigens contributes to the induction
of humoral autoimmunity during tumour necrosis factor alpha blockade;
Annals of the Rheumatic Diseases; 68(6), 2009, p.1022 29
7. Cantaert Tineke, Brouard Sophie, Thurlings Rogier M., Pallier Annaick,
Salinas Gabriela Franco, Braud Christophe, Klarenbeek Paul L., de Vries
Niek, Zhang Yiping, Soulillou Jean Paul, Tak Paul P., Baeten Dominique:
Alterations of the Synovial T Cell Repertoire in Anti Citrullinated Protein
Antibody Positive Rheumatoid Arthritis; Arthritis & Rheumatism - Arthritis
Care & Research; 60(7), 2009, p.1944 56.
8. Raghavan S, Cao D, Widhe M, Roth K, Herrath J, Engström M, Roncador
G, Banham AH, Trollmo C, Catrina AI, Malmström V. FOXP3 expression
in blood, synovial fluid and synovial tissue during inflammatory arthritis
and intra-articular corticosteroid treatment. Ann Rheum Dis. 2009; 68(12):1908-15.
Epub 2008 Dec 9.
9. Vandooren Bernard, Cantaert Tineke, van Lierop Marie José,
Bos Ebo, de Rycke Leen, Veys Eric M., de Keyser Filip, Bresnihan Barry,
Luyten Frank P., Verdonk Peter C., Tak Paul P., Boots Annemieke H., Baeten
Dominique: Melanoma inhibitory activity, a biomarker related to chondrocyte
anabolism, is reversibly suppressed by proinflammatory cytokines in rheumatoid
arthritis; Annals of the Rheumatic Diseases; 68(6), 2009, p.1044 1050.
10. Cantaert Tineke, van Baarsen Lisa G., Wijbrandts Carla A., Thurlings
Rogier M., van de Sande Marleen G., Bos Carina, van der Pouw Tineke Kraan,
Verweij Cor L., Tak Paul P., Baeten Dominique: Type I interferons have
no major influence on humoral autoimmunity in rheumatoid arthritis; Rheumatology,
2010 Jan;49(1):156-66. Epub 2009 Nov 23.
11. Vandooren Bernard, Noordenbos Troy, Ambarus Carmen, Krausz Sarah,
Cantaert Tineke, Yeremenko Nataliya, Boumans Maartje, Lutter Rene, Tak
Paul P., Baeten Dominique: Absence of a Classically Activated Macrophage
Cytokine Signature in Peripheral Spondylarthritis, Including Psoriatic
Arthritis; Arthritis & Rheumatism - Arthritis Care & Research;
2009; 60(4), p.966 975.
12. Bresnihan B, Pontifex E, Thurlings R.M., Vinkenoog M, El-Gabalawy
H, Fearon U, Fitzgerald O, Gerlag D.M., Rooney T, van de Sande M.G., Veale
D, Vos K, Tak P.P: Synovial tissue sublining CD68 expression is a biomarker
of therapeutic response in rheumatoid arthritis clinical trials: consistency
across centers; The Journal of Rheumatology; 36, 2009, p.1800-1802.
13. Vandooren Bernard, Melis Lode, Veys Eric M., Tak Paul P., Baeten
Dominique: In Vitro Spontaneous Osteoclastogenesis of Human Peripheral
Blood Mononuclear Cells Is Not Crucially Dependent on T Lymphocytes; Arthritis
& Rheumatism - Arthritis Care & Research; 60(4), 2009, p.1020
1025.
14. Klaasen Ruth, Thurlings Rogier M., Wijbrandts Carla A., van Kuijk
Arno W., Baeten Dominique, Gerlag Danielle M., Tak Paul P.: The relationship
between synovial lymphocyte aggregates and the clinical response to infliximab
in rheumatoid arthritis: A prospective study; Arthritis & Rheumatism
- Arthritis Care & Research; 60(11), 2009, p.3217 3224.
15. Vandooren B, Yeremenko N, Noordenbos T, Bras J, Tak PP, Baeten D:
Mediators of structural remodeling in peripheral spondylarthritis; Arthritis
Rheum, 2009; 60(12):3534-45.
16. Hamilton John A., Tak Paul P.: The Dynamics of Macrophage Lineage
Populations in Inflammatory and Autoimmune Diseases; Arthritis & Rheumatism
- Arthritis Care & Research; 60(5), 2009, p.1210 1221.
17. Uysal, H. et al. Structure and pathogenicity of antibodies specific
for citrullinated collagen type II in experimental arthritis. J Exp Med
206, 449-462, doi:jem.20081862 [pii]10.1084/jem.20081862 (2009).
18. Richter, C. et al. Ncf1 provides a reactive oxygen species-independent
negative feedback regulation of TLR9-induced IL-12p70 in murine dendritic
cells. J Immunol 182, 4183-4191, doi:182/7/4183 [pii]
10.4049/jimmunol.0800795 (2009).
19. Lindvall, T., Karlsson, J., Holmdahl, R. & Andersson, A. Dissection
of a locus on mouse chromosome 5 reveals arthritis promoting and inhibitory
genes. Arthritis Res Ther 11, R10, doi:ar2599 [pii]
10.1186/ar2599 (2009).
20. Kielland, A. et al. In vivo imaging of reactive oxygen and nitrogen
species in inflammation using the luminescent probe L-012. Free Radic
Biol Med 47, 760-766, doi:S0891-5849(09)00363-3 [pii]
10.1016/j.freeradbiomed.2009.06.013 (2009).
21. Hultqvist, M., Olsson, L. M., Gelderman, K. A. & Holmdahl, R.
The protective role of ROS in autoimmune disease. Trends Immunol 30, 201-208,
doi:S1471-4906(09)00061-1 [pii] 10.1016/j.it.2009.03.004 (2009).
22. Verweij CL. Transcript profiling towards personalised medicine in
rheumatoid arthritis. Neth J Med. 67:364-371 (2009)
23. Verweij CL. Predicting the future of anti-tumor necrosis factor therapy.
Arthritis Res Ther. 11(3):115 (2009)
24. Martin-Trujillo A, van Rietschoten JG, Timmer TC, Milena Rodriguez
F, Huizinga TW, Tak PP, Marsal S, Ibrahim SM, Dijkmans BA, van der Pouw
Kraan TC, Verweij CL. Loss of imprinting of IGF2 characterizes high IGF2mRNA-expressing
type of Fibroblast-like Synoviocytes in Rheumatoid Arthritis. Ann Rheum
Dis. E.Pub ahead (2009)
25. Bos CL, van Baarsen LG, Timmer T, Rustenburg F, Thiesen HJ, Dijkmans
BAC, Overbeek M, van der Pouw Kraan TC, Voskuyl AE, Verweij CL Molecular
subtypes of systemic sclerosis in association with anti-centromere antibodies
and digital ulcers. Genes Immun 10:210-218 (2009)
26. Van Baarsen L, Bos CL, Van der Pouw Kraan TC, Verweij CL. Transcription
profiling of rheumatic diseases. Arthritis Res Ther. 11 :207 (2009)
27. Hultqvist, M., Nandakumar, K.S., Björklund, U., and R. Holmdahl.
The novel small molecule drug Rabeximod is effective in reducing disease
severity of mouse models of autoimmune disorders. Ann Rheum Dis (2009)
68(1);130-5.
28. Hagenow, K., Gelderman, K.A., Hultqvist, M., Merky, P., Bäcklund,
J., Frey, O., Kamradt, T., and R. Holmdahl. Ncf1-associated reduced oxidative
burst promotes IL-33R+ T cell mediated adjuvant-free arthritis in mice.
J Immunol (2009) 15;183(2):874-81
29. Rudnicka W, Burakowski T, Warnawin E, Jastrzebska M, Bik M, Kontny
E, Chorazy-Massalska M, Radzikowska A, Buler M, Maldyk P, Maslinski W.
Functional TLR9 modulates bone marrow B cells from rheumatoid arthritis
patients. Eur J Immunol 2009, 39 (5), 1211-1220.
30. Tokoyoda K, Zehentmeier S, Hegazy AN, Albrecht I, Grün JR, Löhning
M, Radbruch A. Professional memory CD4+ T lymphocytes preferentially reside
and rest in the bone marrow. Immunity. 2009 May;30(5):721-30.
31. Menssen A, Edinger G, Grün JR, Haase U, Baumgrass R, Grützkau
A, Radbruch A, Burmester GR, Häupl T. SiPaGene: A new repository
for instant online retrieval, sharing and meta-analyses of GeneChip expression
data. BMC Genomics. 2009 Mar 5;10:98.
32. Adoptive transfer of IL-10-secreting CD4+CD49b+ regulatory T cells
suppresses ongoing arthritis.
Charbonnier LM, Han WG, Quentin J, Huizinga TW, Zwerina J, Toes RE, Jorgensen
C, Louis-Plence P.
J Autoimmun. 2010 Jun;34(4):390-9. Epub 2009 Oct 31.
33. Association of a single-nucleotide polymorphism in CD40 with the
rate of joint destruction in rheumatoid arthritis.
van der Linden MP, Feitsma AL, le Cessie S, Kern M, Olsson LM, Raychaudhuri
S, Begovich AB, Chang M, Catanese JJ, Kurreeman FA, van Nies J, van der
Heijde DM, Gregersen PK, Huizinga TW, Toes RE, van der Helm-Van Mil AH.
Arthritis Rheum. 2009 Aug;60(8):2242-7.
34. Loss of imprinting of IGF2 characterises high IGF2 mRNA-expressing
type of fibroblast-like synoviocytes in rheumatoid arthritis.
Martin-Trujillo A, van Rietschoten JG, Timmer TC, Rodríguez FM,
Huizinga TW, Tak PP, Marsal S, Ibrahim SM, Dijkmans BA, van der Pouw Kraan
TC, Verweij CL.
Ann Rheum Dis. 2010 Jun;69(6):1239-42. Epub 2009 Jun 24.
35. Diagnostic value of anti-MCV antibodies in differentiating early
inflammatory arthritis.
Damjanovska L, Thabet MM, Levarth EW, Stoeken-Rijsbergen G, van der Voort
EI, Toes RE, Huizinga TW, van der Helm-van Mil AH.
Ann Rheum Dis. 2010 Apr;69(4):730-2. Epub 2009 May 17.
36. The TRAF1-C5 region on chromosome 9q33 is associated with multiple
autoimmune diseases.
Kurreeman FA, Goulielmos GN, Alizadeh BZ, Rueda B, Houwing-Duistermaat
J, Sanchez E, Bevova M, Radstake TR, Vonk MC, Galanakis E, Ortego N, Verduyn
W, Zervou MI, Roep BO, Dema B, Espino L, Urcelay E, Boumpas DT, van den
Berg LH, Wijmenga C, Koeleman BP, Huizinga TW, Toes RE, Martin J; AADEA
Group; SLEGEN Consortium.
Ann Rheum Dis. 2010 Apr;69(4):696-9. Epub 2009 May 10.
37. Association of the 6q23 region with the rate of joint destruction
in rheumatoid arthritis.
Scherer HU, van der Linden MP, Kurreeman FA, Stoeken-Rijsbergen G, Cessie
S, Huizinga TW, van der Helm-van Mil AH, Toes RE.
Ann Rheum Dis. 2010 Mar;69(3):567-70. Epub 2009 Apr 14.
38. Sustained improvement of vascular endothelial function during anti-TNFalpha
treatment in rheumatoid arthritis patients.
Sidiropoulos PI, Siakka P, Pagonidis K, Raptopoulou A, Kritikos H, Tsetis
D, Boumpas DT. Scand J Rheumatol. 2009 Jan-Feb;38(1):6-10.
39. Specific interaction between genotype, smoking and autoimmunity to
citrullinated alpha-enolase in the etiology of rheumatoid arthritis.
Mahdi H, Fisher BA, Källberg H, Plant D, Malmström V, Rönnelid
J, Charles P, Ding B, Alfredsson L, Padyukov L, Symmons DP, Venables PJ,
Klareskog L, Lundberg K. Nat Genet. 2009 Dec;41(12):1319-24.
40. Gene-environment interaction between the DRB1 shared epitope and
smoking in the risk of anti-citrullinated protein antibody-positive rheumatoid
arthritis: all alleles are important. Lundström E, Källberg
H, Alfredsson L, Klareskog L, Padyukov L. Arthritis Rheum. 2009 Jun;60(6):1597-603
41. Specific association of type 1 diabetes mellitus with anti-cyclic
citrullinated peptide-positive rheumatoid arthritis. Liao KP, Gunnarsson
M, Källberg H, Ding B, Plenge RM, Padyukov L, Karlson EW, Klareskog
L, Askling J, Alfredsson L. Arthritis Rheum. 2009 Mar;60(3):653-60.
42. Different patterns of associations with anti-citrullinated protein
antibody-positive and anti-citrullinated protein antibody-negative rheumatoid
arthritis in the extended major histocompatibility complex region. Ding
B, Padyukov L, Lundström E, Seielstad M, Plenge RM, Oksenberg JR,
Gregersen PK, Alfredsson L, Klareskog L. Arthritis Rheum. 2009 Jan;60(1):30-8.
43. Vandooren B et al, Absence of a classically activated macrophage
cytokine signature in peripheral spondyloarthritis, including psoriatic
arthritis Arthritis Rheum. 2009 Apr;60(4):966-75.
2010
1. van Kuijk AW, Wijbrandts CA, Vinkenoog M, Zheng TS, Reedquist KA,
Tak PP; TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid
arthritis compared to psoriatic arthritis and its response to TNF blockade;
Annals of the Rheumatic Diseases; 69 (1), 2010 p. 301-304.
2. Grisar J., Munk M., Steiner C.W., Tohidast-Akrad M., Steiner G.,Smolen
J.S.: Expression pattern of CD44 splice variants in patients with rheumatoid
arthritis; Submitted for publication, 2010
3. Martin-Trujillo A, van Rietschoten JGI, Timmer TCG, Rodríguez
FM, Huizinga TWJ, Tak PP, Marsal S, Ibrahim SM, Dijkmans BAC, van der
Pouw Kraan TCTM, Verweij CL. Loss of imprinting of IGF2 characterises
high IGF2 mRNA-expressing type of fibroblast-like synoviocytes in rheumatoid
arthritis. ANN RHEUM DIS 2010;69(6):1239-1242.
4. Stanczyk J, Ospelt C, Karouzakis E, Filer A, Raza K, Kolling C, Gay
R, Buckley CD, Tak PP, Gay S, Kyburz D. Altered expression of miR-203
in rheumatoid arthritis synovial fibroblasts and its role in fibroblast
activation. ARTH RHEUM/AR C RES 2010; [Epub ahead of print]
5. van Kuijk AWR, Vergunst CE, Gerlag DM, Bresnihan B, Gomez-Reino JJ,
Regine R, Verschueren PC, van de Leij C, Maas M, Kraan MC, Tak PP. CCR5
blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled
clinical trial. ANN RHEUM DIS 2010;69(11):2013-2016.
6. van Baarsen LGM, Wijbrandts CA, Timmer TCG, van der Pouw Kraan TCTM,
Tak PP, Verweij CL. Synovial tissue heterogeneity in rheumatoid arthritis
in relation to disease activity and biomarkers in peripheral blood. ARTH
RHEUM/AR C RES 2010;62(6):1602-1607.
7. van Baarsen LGM, Wijbrandts CA, Rustenburg F, Cantaert T, van der
Pouw Kraan TCTM, Baeten DL, Dijkmans BAC, Tak PP, Verweij CL. Regulation
of interferon response gene activity during infliximab treatment in rheumatoid
arthritis is associated with clinical response to treatment. ARTHRITIS
RES THER 2010;12(1):R11.
8. van de Sande MGH, Gerlag DM, Lodde BM, van Baarsen LG, Alivernini
S, Codullo V, Felea I, Vieira-Sousa E, Fearon U, Reece R, Montecucco C,
Veale DJ, Pitzalis C, Emery P, Klareskog L, McInnes IB, Tak PP. Evaluating
antirheumatic treatments using synovial biopsy: a recommendation for standardisation
to be used in clinical trials. Ann Rheum Dis. 2010 Nov 24.
9. Uysal, H. et al. Antibodies to citrullinated proteins: molecular interactions
and arthritogenicity. Immunol Rev 233, 9-33, doi:IMR853 [pii]
10.1111/j.0105-2896.2009.00853.x (2010).
10. Snir, O. et al. Antibodies to several citrullinated antigens are
enriched in the joints of rheumatoid arthritis patients. Arthritis Rheum
62, 44-52, doi:10.1002/art.25036 (2010).
11. Rintisch, C. et al. Finemapping of the arthritis QTL Pia7 reveals
co-localization with Oia2 and the APLEC locus. Genes Immun 11, 239-245,
doi:gene20102 [pii]
10.1038/gene.2010.2 (2010).
12. Hultqvist, M. et al. Positioning of a Polymorphic Quantitative Trait
Nucleotide in the Ncf1 Gene Controlling the Oxidative Burst Response and
Arthritis Severity in Rats. Antioxid Redox Signal in revision (2010).
13. Thurlings RM, Boumans M, Tekstra J, van Roon JA, Vos K, van Westing
DM, van Baarsen LG, Bos C, Kirou KA, Gerlag DM, Crow MK, Bijlsma JW, Verweij
CL, Tak PP. The relationship between the type I interferon signature and
the response to rituximab in rheumatoid arthritis. Arthritis Rheum. 2010
Sept. In press
14. van Baarsen LG, Wijbrandts CA, Gerlag DM, Rustenburg F, van der Pouw
Kraan TC, Dijkmans BA, Tak PP, Verweij CL.Pharmacogenomics of infliximab
treatment using peripheral blood cells of patients with rheumatoid arthritis.
Genes Immun. 2010 Jun 17. [Epub ahead of print]
15. van Baarsen LG, Wijbrandts CA, Timmer TC, van der Pouw Kraan TC,
Tak PP, Verweij CL.Synovial tissue heterogeneity in rheumatoid arthritis
in relationship to disease activity and biomarkers in peripheral blood.
Arthritis Rheum. Feb 22. (2010)[Epub ahead of print]
16. van Baarsen LG, Bos WH, Rustenburg F, van der Pouw Kraan TC, Wolbink
GJ, Dijkmans BA, van Schaardenburg D, Verweij CL. Gene expression profiling
in autoantibody-positive patients with arthralgia predicts development
of arthritis. Arthritis Rheum. 62:694-704 (2010)
17. van Baarsen LG, Wijbrandts CA, Rustenburg F, Cantaert T, van der Pouw
Kraan TC, Baeten DL, Dijkmans BA, Tak PP, Verweij CL. Regulation of IFN
response gene activity during infliximab treatment in rheumatoid arthritis
is associated with clinical response to treatment. Arthritis Res Ther.
12:R11 (2010)
18. Cantaert T, van Baarsen LG, Wijbrandts CA, Thurlings RM, van de Sande
MG, Bos C, van der Pouw TK, Verweij CL, Tak PP, Baeten DL. Type I interferons
have no major influence on humoral autoimmunity in rheumatoid arthritis.
Rheumatology (Oxford). 49:156-66 (2010)
19. Maciejewska Rodrigues H, Al-Shamisi M, Hemmatazad H, Ospelt C, Bouton
MC, Jäger D, Cope AP, Charles P, Plant D, Distler JHW, Gay RE, Michel
BA, Knuth A, Neidhart M, Gay S, Jüngel A. Functional autoantibodies
against serpin E2 in rheumatoid arthritis. Arthritis Rheum. 2010 Jan;62(1):93-104.
20. Darren Plant, Edward Flynn, Hamdi Mbarek, Philippe Dieudé,
Francois Cornelis, Lisbeth Ärlestig, Solbritt Rantapää
Dahlqvist, George Goulielmos, Dimitrios T Boumpas, Prodromos Sidiropoulos,
Julia S Johansen, Lykke M. Ørnbjerg, Merete Lund Hetland, Lars
Klareskog, Andrew Filer, Christopher D Buckley, Karim Raza, Torsten Witte,
Reinhold E. Schmidt, Jane Worthington. Investigation of potential non-HLA
rheumatoid arthritis susceptibility loci in a European cohort increases
the evidence for 9 markers. Ann Rheum Dis, 69(8), 1548-1553.
21. Plant, D., Farragher, T., Flynn, E., Martin, P., Eyre, S., Bunn,
D., Worthington, J., Symmons, D., Barton, A. & Thomson, W (2010).
A genetic marker at the OLIG3/TNFAIP3 locus associates with methotrexate
continuation in early inflammatory polyarthritis: results from the Norfolk
Arthritis Register. The pharmacogenomics journal (2010) 1-6.
22. Hultqvist, M., Nandakumar, K.S., Björklund, U., and R. Holmdahl.
Rabeximod reduces arthritis severity in mice by decreasing activation
of inflammatory cells. Ann Rhem Dis (2010) 69;1527-1532
23. Kuca-Warnawin E, Burakowski T, Kurowska W, Prochorec-Sobieszek M,
Radzikowska A, Massalska M, Maldyk P, Kontny E, Maslinski W. Elevated
number of recently activated T cells in bone marrow of patients with rheumatoid
arthritis: a role for interleukin 15? Ann Rheum Dis 2010:, doi: 10.1136/ard2009.124966
24. Albrecht I, Niesner U, Janke M, Menning A, Loddenkemper C, Kühl
AA, Lepenies I, Lexberg MH, Westendorf K, Hradilkova K, Grün J, Hamann
A, Epstein JA, Chang HD, Tokoyoda K, Radbruch A. Persistence of effector
memory Th1 cells is regulated by Hopx. Eur J Immunol. 2010 Nov;40(11):2993-3006.
25. Yoshida T, Mei H, Dörner T, Hiepe F, Radbruch A, Fillatreau S,
Hoyer BF. Memory B and memory plasma cells. Immunol Rev. 2010;237(1):117-39.
26. Smiljanovic B, Grün JR, Steinbrich-Zöllner M, Stuhlmüller
B, Häupl T, Burmester GR, Radbruch A, Grützkau A, Baumgrass
R. Defining TNF-a- and LPS-induced gene signatures in monocytes to unravel
the complexity of peripheral blood transcriptomes in health and disease.
J Mol Med. 2010 Oct;88(10):1065-79.
27. Grützkau A, Radbruch A.Small but mighty: how the MACS-technology
based on nanosized superparamagnetic particles has helped to analyze the
immune system within the last 20 years. Cytometry A. 2010 Jul;77(7):643-7.
28. Häupl T, Stuhlmüller B, Grützkau A, Radbruch A, Burmester
GR. Does gene expression analysis inform us in rheumatoid arthritis? Ann
Rheum Dis. 2010 Jan;69 Suppl 1:i37-42.
29. Stuhlmüller B, Häupl T, Hernandez MM, Grützkau A,
Kuban RJ, Tandon N, Voss JW, Salfeld J, Kinne RW, Burmester GR. CD11c
as a transcriptional biomarker to predict response to anti-TNF monotherapy
with adalimumab in patients with rheumatoid arthritis. Clin Pharmacol
Ther. 2010 Mar;87(3):311-21.
30. Towards a data-driven evaluation of the 2010 ACR/EULAR criteria for
rheumatoid arthritis: Is it sensible to look at levels of rheumatoid factor?
van der Linden MP, Batstra MR, Bakker-Jonges LE, Detert J, Bastian H,
Scherer HU, Toes RE, Burmester GR, Mjaavatten MD, Kvien TK, Huizinga TW,
van der Helm-van Mil AH.
Arthritis Rheum. 2010 Dec 15. [Epub ahead of print]
31. Anti-citrullinated protein antibodies have a low avidity compared
with antibodies against recall antigens.
Suwannalai P, Scherer HU, van der Woude D, Ioan-Facsinay A, Jol-van der
Zijde CM, van Tol MJ, Drijfhout JW, Huizinga TW, Toes RE, Trouw LA.
Ann Rheum Dis. 2010 Nov 10. [Epub ahead of print]
32. PADI4 polymorphism predisposes male smokers to rheumatoid arthritis.
Kochi Y, Thabet MM, Suzuki A, Okada Y, Daha NA, Toes RE, Huizinga TW,
Myouzen K, Kubo M, Yamada R, Nakamura Y, Yamamoto K.
Ann Rheum Dis. 2010 Nov 9. [Epub ahead of print]
33. DX5(+)CD4(+) T cells modulate cytokine production by CD4(+) T cells
towards IL-10 via the production of IL-4.
Han WG, van der Voort EI, el Bannoudi H, Louis-Plence P, Huizinga TW,
Toes RE.
Eur J Immunol. 2010 Oct;40(10):2731-40.
34. Long-term impact of delay in assessment of patients with early arthritis.
van der Linden MP, le Cessie S, Raza K, van der Woude D, Knevel R, Huizinga
TW, van der Helm-van Mil AH.
Arthritis Rheum. 2010 Dec;62(12):3537-46. doi: 10.1002/art.27692.
35. Epitope spreading of the anti-citrullinated protein antibody response
occurs before disease onset and is associated with the disease course
of early arthritis.
van der Woude D, Rantapää-Dahlqvist S, Ioan-Facsinay A, Onnekink
C, Schwarte CM, Verpoort KN, Drijfhout JW, Huizinga TW, Toes RE, Pruijn
GJ.
Ann Rheum Dis. 2010 Aug;69(8):1554-61. Epub 2010 May 6.
36. The ACPA isotype profile reflects long-term radiographic progression
in rheumatoid arthritis.
37.van der Woude D, Syversen SW, van der Voort EI, Verpoort KN, Goll
GL, van der Linden MP, van der Helm-van Mil AH, van der Heijde DM, Huizinga
TW, Kvien TK, Toes RE. Ann Rheum Dis. 2010 Jun;69(6):1110-6. Epub 2010
May 3.
38. TRAF1/C5 polymorphism is not associated with increased mortality
in rheumatoid arthritis: two large longitudinal studies.
van Nies JA, Marques RB, Trompet S, de Jong Z, Kurreeman FA, Toes RE,
Jukema JW, Huizinga TW, van der Helm-van Mil AH.
Arthritis Res Ther. 2010;12(2):R38. Epub 2010 Mar 5.
39. Glycan profiling of anti-citrullinated protein antibodies isolated
from human serum and synovial fluid.
Scherer HU, van der Woude D, Ioan-Facsinay A, el Bannoudi H, Trouw LA,
Wang J, Häupl T, Burmester GR, Deelder AM, Huizinga TW, Wuhrer M,
Toes RE.
Arthritis Rheum. 2010 Jun;62(6):1620-9.
40. Evidence for a functional role of IgE anticitrullinated protein antibodies
in rheumatoid arthritis.
Schuerwegh AJ, Ioan-Facsinay A, Dorjée AL, Roos J, Bajema IM, van
der Voort EI, Huizinga TW, Toes RE.
Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2586-91. Epub 2010 Jan 25.
41. Protection against anti-citrullinated protein antibody-positive rheumatoid
arthritis is predominantly associated with HLA-DRB1*1301: a meta-analysis
of HLA-DRB1 associations with anti-citrullinated protein antibody-positive
and anti-citrullinated protein antibody-negative rheumatoid arthritis
in four European populations. van der Woude D, Lie BA, Lundström
E, Balsa A, Feitsma AL, Houwing-Duistermaat JJ, Verduijn W, Nordang GB,
Alfredsson L, Klareskog L, Pascual-Salcedo D, Gonzalez-Gay MA, Lopez-Nevot
MA, Valero F, Roep BO, Huizinga TW, Kvien TK, Martín J, Padyukov
L, de Vries RR, Toes RE.
Arthritis Rheum. 2010 May;62(5):1236-45.
42. Identification of citrullinated vimentin peptides as T cell epitopes
in HLA-DR4-positive patients with rheumatoid arthritis.
Feitsma AL, van der Voort EI, Franken KL, el Bannoudi H, Elferink BG,
Drijfhout JW, Huizinga TW, de Vries RR, Toes RE, Ioan-Facsinay A.
Arthritis Rheum. 2010 Jan;62(1):117-25.
43. Neutralization of IL-4 reverses the nonresponsiveness of CD4+ T cells
to regulatory T-cell induction in non-responder mouse strains.
Wang J, Han WG, Foks AC, Huizinga TW, Toes RE.
Mol Immunol. 2010 Nov-Dec;48(1-3):137-46. Epub 2010 Sep 25.
44. Immunodominant T-cell epitopes of hnRNP-A2 associated with disease
activity in patients with rheumatoid arthritis.
Trembleau S, Hoffmann M, Meyer B, Nell V, Radner H, Zauner W, Hammer J,
Aichinger G, Fischer G, Smolen J, Steiner G.
Eur J Immunol. 2010 Jun;40(6):1795-808.
45. Gait changes precede overt arthritis and strongly correlate with
symptoms and histopathological events in pristane-induced arthritis.
Hoffmann MH, Hopf R, Niederreiter B, Redl H, Smolen JS, Steiner G.
Arthritis Res Ther. 2010;12(2):R41. Epub 2010 Mar 11.
46. Autoantibody profiling in patients with very early rheumatoid arthritis:
a follow-up study.
Nell-Duxneuner V, Machold K, Stamm T, Eberl G, Heinzl H, Hoefler E, Smolen
JS, Steiner G. Ann Rheum Dis. 2010 Jan;69(1):169-74. Epub .
47. The programmed death 1/programmed death ligand 1 inhibitory pathway
is up-regulated in rheumatoid synovium and regulates peripheral T cell
responses in human and murine arthritis.
Raptopoulou AP, Bertsias G, Makrygiannakis D, Verginis P, Kritikos I,
Tzardi M, Klareskog L, Catrina AI, Sidiropoulos P, Boumpas DT.
Arthritis Rheum. 2010 Jul;62(7):1870-80.
48. Novel role of plasmacytoid dendritic cells in humans: induction of
interleukin-10-producing Treg cells by plasmacytoid dendritic cells in
patients with rheumatoid arthritis responding to therapy.
Kavousanaki M, Makrigiannakis A, Boumpas D, Verginis P.
Arthritis Rheum. 2010 Jan;62(1):53-63.
49. The role of the pro-apoptotic protein Siva in the pathogenesis of
Familial Mediterranean fever: A structural and functional analysis.
Goulielmos GN, Petraki E, Vassou D, Eliopoulos E, Iliopoulos D, Sidiropoulos
P, Aksentijevich I, Kardassis D, Boumpas DT.
Biochem Biophys Res Commun. 2010 Nov 5;402(1):141-6. Epub 2010 Oct 8
50. A genome-wide association study suggests contrasting associations
in ACPA-positive versus ACPA-negative rheumatoid arthritis.
Padyukov L, Seielstad M, Ong RT, Ding B, Rönnelid J, Seddighzadeh
M, Alfredsson L, Klareskog L; the Epidemiological Investigation of Rheumatoid
Arthritis (EIRA) Study Group. Ann Rheum Dis. 2010 Dec 14.
51. Smoking is a major preventable risk factor for rheumatoid arthritis:
estimations of risks after various exposures to cigarette smoke.
Källberg H, Ding B, Padyukov L, Bengtsson C, Rönnelid J, Klareskog
L, Alfredsson L; EIRA Study Group. Ann Rheum Dis. 2010 Dec 13.
52. Evaluating antirheumatic treatments using synovial biopsy: a recommendation
for standardisation to be used in clinical trials.
van de Sande MG, Gerlag DM, Lodde BM, van Baarsen LG, Alivernini S, Codullo
V, Felea I, Vieira-Sousa E, Fearon U, Reece R, Montecucco C, Veale DJ,
Pitzalis C, Emery P, Klareskog L, McInnes IB, Tak PP. Ann Rheum Dis. 2010
Nov 24.
53. Prevention of autoimmune rheumatic disease: state of the art and
future perspectives.
Klareskog L, Gregersen PK, Huizinga TW. Ann Rheum Dis. 2010 Dec;69(12):2062-6.
54. The gene expression profile in the synovium as a predictor of the
clinical response to infliximab treatment in rheumatoid arthritis.
Lindberg J, Wijbrandts CA, van Baarsen LG, Nader G, Klareskog L, Catrina
A, Thurlings R, Vervoordeldonk M, Lundeberg J, Tak PP. PLoS One. 2010
Jun 25;5(6):e11310.
55. Investigation of potential non-HLA rheumatoid arthritis susceptibility
loci in a European cohort increases the evidence for nine markers.
Plant D, Flynn E, Mbarek H, Dieudé P, Cornelis F, Arlestig L, Dahlqvist
SR, Goulielmos G, Boumpas DT, Sidiropoulos P, Johansen JS, Ørnbjerg
LM, Hetland ML, Klareskog L, Filer A, Buckley CD, Raza K, Witte T, Schmidt
RE, Worthington J.
56. Evidence for interaction between 5-hydroxytryptamine (serotonin)
receptor 2A and MHC type II molecules in the development of rheumatoid
arthritis.
Seddighzadeh M, Korotkova M, Källberg H, Ding B, Daha N, Kurreeman
FA, Toes RE, Huizinga TW, Catrina AI, Alfredsson L, Klareskog L, Padyukov
L. Eur J Hum Genet. 2010 Jul;18(7):821-6.
2011
1. van de Sande MGH, de Hair MJH, van der Leij C, Klarenbeek PL, Bos
WH, Smith MD, Maas M, de Vries M, van Schaardenburg D, Dijkmans BAC, Gerlag
DM, Tak PP. Different stages of rheumatoid arthritis: the features of
the synovium in the preclinical phase. Accepted for publication in Ann
Rheum Dis. 2011.
2. van de Sande MGH, Thurlings RM, Boumans MJH, Wijbrandts CA, Modesti
MG, Gerlag DM, Tak PP. Presence of lymphocyte aggregates in the synovium
of early arthritis patients in relationship to diagnosis and outcome:
is it a constant feature over time? Accepted for publication in Ann Rheum
Dis. 2011.
3. Plant, D., Thomson, W., Lunt, M., Flynn, E., Martin, P., Eyre, S.,
Farragher, T., Bunn, D., Worthington, J., Symmons, D. & Barton, A
(2011). The role of rheumatoid arthritis genetic susceptibility markers
in the prediction of erosive disease in patients with early inflammatory
polyarthritis: results from the Norfolk Arthritis Register. Rheumatology
(Oxford, England), 50(1), 58-84.
4. Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated
protein antibodies and contain overlapping and non-overlapping reactivities.
Ioan-Facsinay A, el-Bannoudi H, Scherer HU, van der Woude D, Ménard
HA, Lora M, Trouw LA, Huizinga TW, Toes RE.
Ann Rheum Dis. 2011 Jan;70(1):188-93. Epub 2010 Aug 24.
|
|
